|
Gene: E2F5 |
Gene summary for E2F5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | E2F5 | Gene ID | 1875 |
Gene name | E2F transcription factor 5 | |
Gene Alias | E2F-5 | |
Cytomap | 8q21.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q15329 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1875 | E2F5 | HCC1_Meng | Human | Liver | HCC | 1.37e-77 | 3.53e-01 | 0.0246 |
1875 | E2F5 | HCC2_Meng | Human | Liver | HCC | 3.12e-13 | 4.03e-02 | 0.0107 |
1875 | E2F5 | S014 | Human | Liver | HCC | 5.78e-04 | 1.86e-01 | 0.2254 |
1875 | E2F5 | S015 | Human | Liver | HCC | 4.32e-03 | 2.34e-01 | 0.2375 |
1875 | E2F5 | S016 | Human | Liver | HCC | 2.44e-02 | 1.60e-01 | 0.2243 |
1875 | E2F5 | S027 | Human | Liver | HCC | 3.04e-07 | 5.03e-01 | 0.2446 |
1875 | E2F5 | S028 | Human | Liver | HCC | 6.91e-26 | 7.44e-01 | 0.2503 |
1875 | E2F5 | S029 | Human | Liver | HCC | 2.21e-13 | 5.74e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0421822 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
E2F5 | deletion | Frame_Shift_Del | rs761281897 | c.314delN | p.Lys107SerfsTer11 | p.K107Sfs*11 | Q15329 | protein_coding | TCGA-BR-4292-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
E2F5 | deletion | Frame_Shift_Del | c.265delA | p.Arg89GlyfsTer10 | p.R89Gfs*10 | Q15329 | protein_coding | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
E2F5 | deletion | Frame_Shift_Del | rs761281897 | c.320delA | p.Lys107SerfsTer11 | p.K107Sfs*11 | Q15329 | protein_coding | TCGA-HU-A4H3-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Chemotherapy | ts-1 | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |